Bedrijfsoverzicht
NRx Pharmaceuticals, Inc. is a clinical-stage bio-pharmaceutical enterprise dedicated to the development of novel therapeutics aimed at treating central nervous system disorders, specifically targeting conditions such as suicidal depression, post-traumatic stress disorder, and chronic pain. The company operates within the healthcare sector and functions specifically in the biotechnology industry, positioning itself as a specialized entity focused on high-risk, high-reward drug candidate development rather than established pharmaceutical manufacturing. In terms of scale, the organization employs 29 individuals and holds a market capitalization of $73.41M, while its trailing twelve-month revenue stands at $1.23M. These financial figures indicate that NRx Pharmaceuticals operates as a micro-cap company with limited operational scale, where the revenue base is insufficient to cover its substantial operating expenses, resulting in a significant negative net income that is characteristic of early-stage biotechnology firms prioritizing research and development over immediate profitability.
Financiële gezondheid
The company reported a revenue of $1.23M over the trailing twelve months, yet it generated a net income of -$28,622,000 and an EBITDA of -$16,118,000. The substantial gap between the modest revenue of $1.23M and the net loss of -$28,622,000 reveals an extremely high cost structure driven by the capital-intensive nature of clinical-stage biotechnology, where research and development expenditures far outweigh current sales. Free cash flow for the period was -$805,875, which signifies that the company is burning through its cash reserves to fund operations and drug development activities rather than generating cash from its core business. The gross margin stands at 58.8%, indicating that the cost of goods sold is relatively low compared to revenue, though this does not offset the massive overhead costs reflected in the operating margin of -467.3%. The profit margin is listed as 0.0%, which technically represents the company's inability to generate any profit on sales due to the overwhelming net loss relative to the small revenue base. On the balance sheet, the company holds $7.80M in cash against $631,000 in debt, creating a situation where cash significantly exceeds liabilities, though the debt-to-equity ratio is N/A due to the equity dynamics of the loss. The current ratio is 0.31, which indicates that the company's current assets are less than half of its current liabilities, suggesting potential short-term liquidity challenges if cash burn rates accelerate. Return on Equity is N/A, and the return on assets is -121.8%, metrics that collectively reveal that management is currently utilizing the company's assets to generate significant losses rather than positive returns for shareholders.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A because the company is unprofitable, whereas the forward P/E is 17.08, implying that the market is pricing in anticipated future earnings that do not yet exist in the current financial results. The price to book ratio is -4.41, a negative figure that indicates the market values the company's equity at a significant discount relative to its book value, often seen in speculative biotechnology stocks where the asset base does not fully capture the potential of pipeline assets. The price to sales ratio is 59.93, which suggests the market is willing to pay a high multiple relative to revenue, reflecting the high valuation placed on the company's intellectual property and clinical pipeline rather than current cash flows. Additionally, the EV/EBITDA stands at -4.11, further emphasizing that traditional earnings-based valuation metrics are not applicable due to the negative earnings before interest, taxes, depreciation, and amortization. The 52-week high is $3.84 and the 52-week low is $1.62, meaning the current trading price sits within a range that reflects significant volatility and investor uncertainty regarding the company's path to commercialization. The beta is 1.83, which indicates that the stock price is expected to be nearly twice as volatile as the broader market, exposing investors to heightened risk during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is N/A, and earnings growth year-over-year is N/A, meaning there is no historical data available to compare current performance against the previous year. Since there is no revenue growth or earnings growth to measure, it is impossible to determine if earnings are growing faster or slower than revenue, as both metrics are currently non-existent or negative in a growth context. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available resources and any potential earnings back into research and development rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by a complete absence of current profitability or dividend distribution, relying entirely on the successful execution of future drug candidates to generate value for investors.